Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firecrest: QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
NCT07354516Phase 3Completed
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QLS-111 + latanoprost in open-angle glaucoma (OAG), ocular hypertension. Started Mar 2026; status: completed.
02
Drugs
QLS-111 + latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT07354516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354516.